GlassScriptPhysician profile
Liviu Rappaport
NPI 1629013933
$2,765.90
in general payments reported to CMS, 2019-2025
41 companies · $442 in 2025
The $442 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $836 · 2020: $286 · 2021: $55.94 · 2022: $423 · 2023: $293 · 2024: $429 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,164.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $465.67 | 2019-2025 | Fasenra, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $264.29 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Novo Nordisk INC | $233.70 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Mallinckrodt Hospital Products INC. | $227.22 | 2022-2025 | Acthar |
| Sunovion Pharmaceuticals INC. | $164.78 | 2019-2020 | |
| Pfizer INC. | $129.33 | 2022-2025 | |
| Mylan Specialty L.P. | $108.90 | 2019-2024 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.82 | 2020-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $100.67 | 2019-2023 | |
| Allergan, INC. | $97.97 | 2019-2020 | |
| Amgen INC. | $84.63 | 2023-2025 | Tezspire, Repatha, Otezla |
| Kowa Pharmaceuticals America, INC. | $57.50 | 2019-2023 | Seglentis |
| Viatris Specialty LLC | $49.68 | 2025 | Yupelri |
| Lilly USA, LLC | $46.29 | 2020-2025 | Zepbound |
| Genzyme Corporation | $43.86 | 2019-2025 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Liviu Rappaport listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.